** Shares of Edgewise Therapeutics rise about 17% to $32.28 in premarket trading

** Company says its experimental genetic disorder drug met the main goal in a mid-stage study

** The drug, sevasemten, is being developed to treat Becker Muscular Dystrophy, a rare condition that results in progressive muscle weakness and degeneration

** Sevasemten helped significantly reduce levels of creatine kinase, an enzyme associated with skeletal muscle damage in the study- EWTX

** Up to last close, stock more than doubled YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))